Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q2 2018 (← Previous) (Next →)

Filing Date: Jul 13, 2018

Total Value ($000): $320,525,517 (100.0% shares, 0.0% debt)

Holdings (9)

CRSP CRISPR Therapeutics AG 66.2%

Value ($000) $212,057,436 Shares 3,608,874 Est. Cost $41.27 Unrealized +38.0%

— Audentes Therapeutics, Inc. 14.4%

Value ($000) $46,028,339 Shares 1,204,615 Est. Cost $17810.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 4.7%

Value ($000) $14,953,842 Shares 2,215,384 Est. Cost $20.09 Unrealized -65.8%

— CymaBay Therapeutics, Inc. 4.4%

Value ($000) $14,072,225 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— Achaogen, Inc. 3.5%

Value ($000) $11,094,776 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— ImmuneDesign Corp. 3.1%

Value ($000) $10,047,356 Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Second Sight Medical Products, Inc. 2.3%

Value ($000) $7,458,339 Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— Clovis Oncology, Inc. 1.4%

Value ($000) $4,631,347 Shares 101,855 Est. Cost $56000.00 Unrealized —

— OpGen, Inc. 0.1%

Value ($000) $181,857 Shares 102,167 Est. Cost $1780.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	3,608,874	$212,057,436	66.2%	$41.27	+38.0%	Common Stock	H17182108
—	Audentes Therapeutics, Inc.	1,204,615	$46,028,339	14.4%	$17810.00	—	Common Stock	05070R104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$14,953,842	4.7%	$20.09	-65.8%	Common Stock	67576A100
—	CymaBay Therapeutics, Inc.	1,048,601	$14,072,225	4.4%	$9830.00	—	Common Stock	23257D103
—	Achaogen, Inc.	1,281,152	$11,094,776	3.5%	$13050.00	—	Common Stock	004449104
—	ImmuneDesign Corp.	2,208,210	$10,047,356	3.1%	$7580.00	—	Common Stock	45252L103
—	Second Sight Medical Products, Inc.	4,492,975	$7,458,339	2.3%	$1210.00	—	Common Stock	81362J100
—	Clovis Oncology, Inc.	101,855	$4,631,347	1.4%	$56000.00	—	Common Stock	189464100
—	OpGen, Inc.	102,167	$181,857	0.1%	$1780.00	—	Common Stock	68373L109